General Information on Scleroderma
Disease Details and Frequently Asked Questions
It is a chronic, rare autoimmune rheumatic disorder where an aberrant immune response stimulates fibroblasts to synthesize an excessive amount of 'Collagen' protein, resulting in the skin, blood vessels, and internal organs becoming rigidly hard, fibrotic, and losing their natural elasticity.
Localized Scleroderma (Morphea): It exclusively affects the skin, presenting as circumscribed patches of thickened integument, with absolutely no involvement of the internal organs.
Systemic Sclerosis: The severe, systemic variant where, in addition to the cutaneous manifestations, critical internal organs such as the lungs, heart, kidneys, and esophagus undergo progressive fibrotic hardening and functional decline.
The earliest pathophysiological event involves intense microvascular vasospasms in the digits. Upon exposure to cold temperatures or emotional stress, the fingers turn stark white (ischemia), then blue (cyanosis), and finally bright red (reperfusion hyperemia) within seconds. This is known as Raynaud's phenomenon, serving as the initial presenting complaint in over 90% of scleroderma patients.
The skin progressively becomes taut, indurated, and shiny. Due to severe perioral skin tightening (microstomia), the lips become characteristically thinned, the patient's oral aperture restricts making it difficult to fully open the mouth, and facial expression lines are obliterated, culminating in a typical 'mask-like' facies.
Diagnosis is initiated by a Rheumatologist evaluating the specific cutaneous phenotype (particularly the presence of 'sausage-like' edematous and sclerotic digits). Serological detection of specific autoantibodies (such as Anti-Scl-70 and Anti-centromere) combined with Nailfold Capillaroscopy (to assess microvascular architecture) are definitively diagnostic.
There is no definitive curative therapy to arrest the fibrotic process completely; management is strictly tailored to the specific organ involvement. Vasodilatory medications (calcium channel blockers) are prescribed to alleviate Raynaud's vasospasms. High-dose Proton Pump Inhibitors (PPIs) mitigate severe esophageal reflux. To retard the progression of pulmonary fibrosis or renal crises, systemic immunosuppressants and corticosteroids are strategically employed.
Our health library contents are prepared for informational purposes only and with scientific data available at the time of recording. For all your questions, concerns, diagnosis, or treatment regarding your health, please consult your doctor or a healthcare institution.
